133 related articles for article (PubMed ID: 11228217)
1. Dose-finding study for the use of long-acting gonadotrophin-releasing hormone analogues prior to ovarian stimulation for IVF.
Yim SF; Lok IH; Cheung LP; Briton-Jones CM; Chiu TT; Haines CJ
Hum Reprod; 2001 Mar; 16(3):492-4. PubMed ID: 11228217
[TBL] [Abstract][Full Text] [Related]
2. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).
Olivennes F; Belaisch-Allart J; Emperaire JC; Dechaud H; Alvarez S; Moreau L; Nicollet B; Zorn JR; Bouchard P; Frydman R
Fertil Steril; 2000 Feb; 73(2):314-20. PubMed ID: 10685535
[TBL] [Abstract][Full Text] [Related]
3. Self-control study on reduced-dose depot versus daily administration of gonadotrophin-releasing hormone agonists for pituitary desensitization in in vitro fertilization cycles.
Gao J; Xu YW; Miao BY; Zhou CQ
J Obstet Gynaecol Res; 2014 Jul; 40(7):1901-6. PubMed ID: 25056469
[TBL] [Abstract][Full Text] [Related]
4. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles.
Albuquerque LE; Saconato H; Maciel MC
Cochrane Database Syst Rev; 2002; (3):CD002808. PubMed ID: 12137658
[TBL] [Abstract][Full Text] [Related]
5. Does lower dose of long-acting triptorelin maintain pituitary suppression and produce good live birth rate in long down-regulation protocol for in-vitro fertilization?
Chen X; Feng SX; Guo PP; He YX; Liu YD; Ye DS; Chen SL
J Huazhong Univ Sci Technolog Med Sci; 2016 Apr; 36(2):215-220. PubMed ID: 27072965
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
[TBL] [Abstract][Full Text] [Related]
7. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
8. The use of long- and short-acting forms of gonadotrophin-releasing hormone analogues in women undergoing oocyte donation.
Neuspiller F; Levy M; Remohí J; Ruiz A; Simón C; Pellicer A
Hum Reprod; 1998 May; 13(5):1148-51. PubMed ID: 9647536
[TBL] [Abstract][Full Text] [Related]
9. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
[TBL] [Abstract][Full Text] [Related]
10. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.
European and Middle East Orgalutran Study Group
Hum Reprod; 2001 Apr; 16(4):644-51. PubMed ID: 11278211
[TBL] [Abstract][Full Text] [Related]
11. GnRH antagonist in single-dose applications.
Olivenne F; Ayoubi JM; Fanchin R; Rongières-Bertrand C; Hamamah S; Bouchard P; Frydman R
Hum Reprod Update; 2000; 6(4):313-7. PubMed ID: 10972518
[TBL] [Abstract][Full Text] [Related]
12. Pulsatile subcutaneous versus bolus intramuscular gonadotrophin administration after pituitary suppression with a long-acting gonadotrophin-releasing hormone analogue: a controlled prospective study.
De Geyter C; De Geyter M; Simoni M; Castro E; Bals-Pratsch M; Nieschlag E; Schneider HP
Hum Reprod; 1994 Jun; 9(6):1070-6. PubMed ID: 7962378
[TBL] [Abstract][Full Text] [Related]
13. Comparison of short 7-day and prolonged treatment with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation.
Hazout A; de Ziegler D; Cornel C; Fernandez H; Lelaidier C; Frydman R
Fertil Steril; 1993 Mar; 59(3):596-600. PubMed ID: 8458463
[TBL] [Abstract][Full Text] [Related]
14. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
Borm G; Mannaerts B
Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855
[TBL] [Abstract][Full Text] [Related]
15. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
Ren J; Sha A; Han D; Li P; Geng J; Ma C
Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
[TBL] [Abstract][Full Text] [Related]
16. Effect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: a randomized study.
Dal Prato L; Borini A; Trevisi MR; Bonu MA; Sereni E; Flamigni C
Hum Reprod; 2001 Jul; 16(7):1409-14. PubMed ID: 11425821
[TBL] [Abstract][Full Text] [Related]
17. Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study.
Janssens RM; Lambalk CB; Vermeiden JP; Schats R; Bernards JM; Rekers-Mombarg LT; Schoemaker J
Hum Reprod; 2000 Nov; 15(11):2333-40. PubMed ID: 11056128
[TBL] [Abstract][Full Text] [Related]
18. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
19. Differences in serum LH and FSH levels using depot or daily GnRH agonists in controlled ovarian stimulation: influence on ovarian response and outcome of ART.
Sonntag B; Kiesel L; Nieschlag E; Behre HM
J Assist Reprod Genet; 2005 Aug; 22(7-8):277-83. PubMed ID: 16195824
[TBL] [Abstract][Full Text] [Related]
20. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
